Table 1 Summary of European ancestry samples and imputed variants used in individual variant association analyses

Population	Study/consortium	Study design	Genotyping array	Imputation panel	N controls/unaffected^a	N cases/affected^b	N variants^c
Population-based	OCAC	Case-control	GWAS panels^d	TOPMed	9071	1745	142,163,775
			iCOGS	TOPMed	28,706	2661	142,163,775
			OncoArray	TOPMed	67,110	10,955	142,163,775
	UKBB	Nested case-control	UK BiLEVE Axiom Array and UK Biobank Axiom Array	UK10K and HRC	244,529	848	59,918,121
BRCA1/2 carriers	CIMBA	Retrospective cohort	iCOGS	TOPMed	3947	632	80,292,260
BRCA1/2 carriers	CIMBA	Retrospective cohort	OncoArray	TOPMed	24,992	3042	104,435,671

OCAC Ovarian Cancer Association Consortium, UKBB UK Biobank, CIMBA Consortium of Investigators of Modifiers of BRCA1 and BRCA2.
^aNumber of controls for population-based studies. UKBB analyses considered prevalent and incident cases to maximise number of cases. Number of carriers censored as unaffected for BRCA1/2 carriers.
^bNumber of EOC cases for population-based studies. Number of carriers censored as affected with EOC for BRCA1/2 carriers.
^cNumber of genotyped and well-imputed (imputation accuracy r² > 0.30) genetic variants available for statistical analyses.
^dThe five GWAS panels were from the UK GWAS, US GWAS, Poland GWAS, Mayo Clinic Ovarian Cancer Study GWAS and the Brigham and Women’s Hospital GWAS.

Quick links

Search